Breaking News Instant updates and real-time market news.

MAT

Mattel

$10.80

-0.25 (-2.26%)

, TSLA

Tesla

$217.08

4.18 (1.96%)

09:02
06/12/19
06/12
09:02
06/12/19
09:02

Fly Intel: Pre-market Movers

HIGHER: Mattel (MAT), up 6% after LA Times reported the company rejected another unsolicited offer by MGA Entertainment... Tesla (TSLA), up 3% after its annual shareholder meeting... CymaBay (CBAY), up 8% after Raymond James analyst Steven Seedhouse upgraded the stock to Strong Buy from Outperform citing the upside potential he sees following yesterday's pullback in the stock... MagnaChip (MX), up 22% after after raising Q2 revenue guidance... Synlogic (SYBX), up 22% after announcing a platform collaboration to accelerate expansion and development of its pipeline of synthetic biotic medicines using Ginkgo's Bioworks cell programming platform. DOWN AFTER EARNINGS: Dave & Buster's (PLAY), down 17%. ALSO LOWER: Trade Desk (TTD), down 5% after Nomura Instinet analyst Mark Kelley downgraded shares to Reduce from Neutral with an unchanged price target of $144. The company's underlying business fundamentals, "while relatively solid, are out of sync with near- to medium-term investor expectations and the story being told," Kelley tells investors... Medidata (MDSO), down 4% after announcing the signing of a definitive agreement for Dassault (DASTY) to acquire the company in an all-cash transaction at a price of $ 92.25 per share, representing an enterprise value of $5.8B... Lam Research (LRCX), down 3% after Evercore ISI analyst C.J. Muse downgraded the stock to In Line from Outperform and lowered his price target for the shares to $195 from $225. An estimate reset in the second half of 2019, combined with a pushout of a memory recovery to the second half of 2020 from the first half, creates headwinds that will make it difficult for the shares to move higher over the near-term, Muse said.

MAT

Mattel

$10.80

-0.25 (-2.26%)

TSLA

Tesla

$217.08

4.18 (1.96%)

CBAY

CymaBay

$6.05

-5.035 (-45.44%)

SYBX

Synlogic

$6.27

-0.06 (-0.95%)

MX

MagnaChip

$8.84

0.06 (0.68%)

PLAY

Dave & Buster's

$51.55

0.98 (1.94%)

TTD

Trade Desk

$249.29

-0.71 (-0.28%)

MDSO

Medidata

$94.75

3.97 (4.37%)

LRCX

Lam Research

$189.90

-0.18 (-0.09%)

  • 12

    Jun

  • 12

    Jun

  • 12

    Jun

  • 13

    Jun

  • 23

    Jun

  • 30

    Jul

MAT Mattel
$10.80

-0.25 (-2.26%)

02/08/19
MKMP
02/08/19
NO CHANGE
Target $15
MKMP
Neutral
Mattel price target raised to $15 from $12 at MKM Partners
MKM Partners analyst Eric Handler raised his price target on Mattel to $15 after its Q4 results surprised to the upside. The analyst also keeps his Neutral rating, noting that while the cost cuts have contributed to the earnings beat, the "revenue turnaround is still a work in progress".
10/26/18
JEFF
10/26/18
NO CHANGE
Target $13
JEFF
Hold
Jefferies says Mattel valuation 'still stretched,' cuts target to $13
At first glance, Mattel's earnings report "was in range," but unpacking the results uncovered a "more challenging set of facts" with sales down 10%, Jefferies analyst Stephanie Wissink tells investors in a post-earnings research note. She lowered her estimates for Mattel and dropped her price target for the shares to $13 from $14. The multiple at current share levels is " still stretched," says Wissink.
12/24/18
BMOC
12/24/18
NO CHANGE
Target $20
BMOC
Spin Master licensing deal with Warner negative for Mattel, says BMO Capital
BMO Capital analyst Gerrick Johnson says the Friday report of a DC superheroes licensing deal between Toys R Us Spin Master and Warner is a negative for Mattel. While the report has not been confirmed, the analyst believes that the business will be lost after 2019. Longer term, the analyst keeps his Outperform rating and $20 price target on Mattel and believes that its management "can facilitate needed changes in culture, product development, digital content, and partner relationships to drive sales and earnings growth."
02/26/19
BMOC
02/26/19
NO CHANGE
Target $20
BMOC
Outperform
Mattel price target lowered to $20 from $23 at BMO Capital
BMO Capital analyst Gerrick Johnson lowered his price target on Mattel to $20 after attending the company's Toy Fair analyst event. The analyst states that while he is "encouraged" by its efforts to reposition business toward profitable growth, the turnaround involving "SKU rationalization,process improvement, cost reduction, and infrastructure investments" could take longer than he anticipated. Longer term, Johnson keeps his Outperform rating on Mattel and believes that the stock still has "value that will continue to be unlocked" amid the management's transformation efforts.
TSLA Tesla
$217.08

4.18 (1.96%)

06/12/19
WEDB
06/12/19
NO CHANGE
Target $230
WEDB
Neutral
Tesla still facing 'fork in the road scenario,' says Wedbush
Wedbush analyst Daniel Ives notes that Tesla held its annual shareholder meeting, where CEO Elon Musk provided an update on Model Y as well as Gigafactory-China, outlined the roadmap and status for the Pickup and Semi, while providing insights into the current quarter, Model 3 demand, and battery production. The analyst highlights that Musk stated the company has decent shot for a record quarter on all metrics, Tesla's product roadmap relies on its ability to scale the production of cells and battery packs, and Tesla is on target to grow its entire fleet by 60% to 80% this year but that it is "hard to be profitable" at that rate of growth. Ives continues to believe in the near-term Musk and Tesla are facing a "fork in the road scenario" with Model 3 demand, and thinks the company needs a significant rebound in Model 3 deliveries this quarter as well as into the back half of 2019 for it to provide sustained profitability. The analyst has a Neutral rating and a $230 price target on the shares.
06/12/19
BARD
06/12/19
NO CHANGE
Target $340
BARD
Outperform
Tesla annual meeting 'positive step' toward rebuilding credibility, says Baird
Baird analyst Ben Kallo believes Tesla's annual meeting last night was a "positive step" towards rebuilding investor credibility. He likes the stock's setup into the balance of the year. Management indicated demand is not a concern, Kallo tells investors in a research note. The analyst thinks the Tesla narrative is "overly negative" and that "bear arguments will be disproven in the coming weeks and months." There are several catalysts over the next few months which could create a challenging short environment, says Kallo. These include the company's delivery release by July 4 with potentially record volumes, a potential cash flow positive quarter, and the battery and powertrain analyst day expected this summer, according to Kallo. The analyst also thinks short covering over the next few weeks "could provide an incremental buyer" for Tesla shares. He keeps an Outperform rating on the name with a $340 price target. Tesla in premarket trading is up $5.61 to $222.71.
06/11/19
MSCO
06/11/19
NO CHANGE
Target $230
MSCO
Equal Weight
Tesla's Autonomy business underappreciated and undervalued, says Morgan Stanley
Morgan Stanley analyst Adam Jonas said efforts in recent years by auto companies such as General Motors (GM) and Ford (F) to focus on mobility have created a currency to attract and retain talent, created the opportunity for new partnerships out of the auto industry and increased the chances to bring in new capital and fund projects at "potentially far more attractive" costs. In this context, he thinks investors underappreciate and undervalue Tesla's Autonomy business, though he values the tech assets in the business at $45 per Tesla share. Given the elevated level of turnover of executives in recent quarters, he sees talent retention and continued access to capital as important priorities for Tesla, added Jonas, who keeps an Equal Weight rating and $230 price target on the stock.
06/10/19
06/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Buy from Neutral at Roth Capital with analyst Craig Irwin saying while he believes rising battery costs are likely to be a 2019 margin headwind, demand from China will likely be stronger than most anticipate, reducing the potential for lowered 2019 unit guidance. 2. Analog Devices (ADI) double upgraded to Buy from Sell at Goldman Sachs with analyst Toshiya Hari saying he is turning more bullish on the company as he believes analog units are tracking below trend. 3. United Technologies (UTX) upgraded to Buy from Neutral at Seaport Global with analyst Josh Sullivan saying at first glance, the company's merger-of-equals with Raytheon (RTN) offers a "compelling combination" in large defense and commercial aerospace growth verticals. 4. Adecoagro (AGRO) upgraded to Buy from Neutral at Citi with analyst Fernanda Perez Da Cunha citing the improvement in commodity prices and a slight reduction in long term maintenance capital expenditures for sugar and ethanol for the upgrade. 5. Sirius XM (SIRI) upgraded to Outperform from Neutral at Credit Suisse with analyst Brian Russo saying the stock decline has brought an attractive risk/reward opportunity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CBAY CymaBay
$6.05

-5.035 (-45.44%)

06/12/19
CANT
06/12/19
NO CHANGE
Target $20
CANT
Overweight
CymaBay selloff yesterday brings buying opportunity, says Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle says the selloff yesterday in shares of CymaBay Therapeutics strengthens her conviction and presents a buying opportunity. The 52-week biopsy data in early 2020 "remain very much in play from a scientific perspective, but now with much greater upside potential from a stock perspective," Merle tells investors in a research note. While the analyst found the lack of fat benefit at week 12 surprising, she says her thesis on seladelpar in nonalcoholic steatohepatitis is that there are many biological reasons why the drug could show "strong" 52-biopsy data independent of fat changes. There is undue investor focus on MRI-PDFF, making NASH a "very large piece of optionality early next year," says the analyst. Merle reiterates an Overweight rating on CymaBay with a $20 price target. The stock closed yesterday down 45%, or $5.04, to $6.05.
06/11/19
RAJA
06/11/19
UPGRADE
Target $19
RAJA
Strong Buy
CymaBay upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded CymaBay to Strong Buy from Outperform citing the upside potential he sees following today's pullback in the stock. He keeps a $19 price target on the shares, calling today's reaction to the surrogate endpoint data "overblown."
06/11/19
PIPR
06/11/19
NO CHANGE
Target $8
PIPR
Overweight
Piper cuts CymaBay price target to $8 on 'worst case' results for NASH trial
Piper Jaffray analyst Tyler Van Buren said he did not anticipate that placebo would perform better than seladelpar in CymaBay Therapeutics' (CBAY) Phase 2b study of the drug for the treatment of nonalcoholic steatohepatitis. Calling the NASH trial results a "worst case scenario," Van Buren sees significant risk to the final 52-week data read-out and removed all expectations in NASH from his model. He said the data make seladelpar seem similar to Genfit's (GNFT) elafibranor, though seladelpar has not yet shown improvements in good cholesterol, glucose homeostatis, or insulin resistance. While Van Buren cut his price target on CymaBay shares to $8 from $30 based on the trial results, he keeps an Overweight rating on the shares given the sharp pullback this morning and the support he sees from the company's remaining cash and residual opportunity.
06/07/19
LEER
06/07/19
NO CHANGE
Target $22
LEER
Outperform
FDA news has 'nothing to do' with CymaBay's programs, says SVB Leerink
SVB Leerink analyst Pasha Sarraf says that CymaBay Therapeutics is down on an "overreaction" to the FDA's recommendation regarding endpoint for compensated cirrhosis. In a research note to investors , Sarraf says he recommends purchasing at these levels, saying he continues to believe the the stock is likely to pop on the interim results from the MRI-PDFF results, which have not yet been announced and feels the FDA's announcement regarding compensated cirrhosis has "absolutely nothing to do" with CymaBay's programs. Sarraf has an Outperform rating and $22 price target on CymaBay shares.
SYBX Synlogic
$6.27

-0.06 (-0.95%)

04/30/19
04/30/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zoom Video (ZM) initiated with an Outperform at Bernstein and a Neutral at Rosenblatt. 2. NeoPhotonics (NPTN) initiated with a Buy at MKM Partners. 3. PennantPark (PNNT) initiated with an Outperform at Raymond James. 4. Jacobs Engineering (JEC) reinstated with an Overweight at Barclays. 5. Synlogic (SYBX) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/19
BTIG
02/12/19
INITIATION
Target $22
BTIG
Buy
Synlogic initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated Synlogic with a Buy rating and a price target of $22. The analyst cites the company's work "to correct inborn errors of metabolism via addition of key detoxification pathways in commensal bacteria", its use of "E. coli Nissle as a gene introduction vector recognized as safe in humans", and its expected release of "important prrof of concept data for both lead programs in phenylketonuria and urea cycle disorders later this year."
04/30/19
JEFF
04/30/19
INITIATION
Target $18
JEFF
Buy
Synlogic initiated with a Buy at Jefferies
Jefferies analyst Chris Howerton started Synlogic with a Buy rating and $18 price target. The analyst views the company's "Synthetic Biotics" platform as a "novel and ingenious way to target a variety of diseases."
12/13/18
CHDN
12/13/18
INITIATION
Target $20
CHDN
Buy
Synlogic initiated with a Buy at Chardan
Chardan analyst Taylor Feehley resumed Synlogic with a Buy and $20 price target.
MX MagnaChip
$8.84

0.06 (0.68%)

10/23/18
ROTH
10/23/18
NO CHANGE
Target $13
ROTH
Buy
MagnaChip price target lowered to $13 from $18 at Roth Capital
Roth Capital analyst Suji Desilva lowered his price target for MagnaChip to $13 from $18 ahead of quarterly results to reflect broader semiconductor stock weakness. The analyst reiterates a Buy rating on the shares.
PLAY Dave & Buster's
$51.55

0.98 (1.94%)

06/12/19
JEFF
06/12/19
NO CHANGE
Target $56
JEFF
Buy
Dave & Buster's price target lowered to $56 from $60 at Jefferies
Jefferies analyst Andy Barish lowered his price target for Dave & Buster's to $56 from $60 citing the company's same-store-sales miss in Q1. The analyst, however, keeps a Buy rating on the shares. He still believes management's strategy is "sound," although he admits the "disappointing" Q1 suggests the turnaround in F&B is still some ways off.
06/12/19
06/12/19
DOWNGRADE
Target $47

Hold
Dave & Buster's cut to Hold at SunTrust on 'competition and cannibalization'
As previously reported, SunTrust analyst Jake Bartlett downgraded Dave & Buster's to Hold from Buy and cut his price target to $47 from $64 after the company's disappointing Q1 results. The analyst notes that comps over the past 6 weeks of the quarter turned negative despite Dave & Buster's launch of a new VR game, adding that while he continues to expect competition and cannibalization to pressure the company's margins by about 400bps, he no longer sees the company's efforts to offset those headwinds as sufficient. Bartlett also cuts his SSS outlook for FY19 to down 0.7% from up 1.0% and for FY20 to flat from up 1%. Bartlett adds that without positive comps, multiple expansion for Dave & Buster's is unlikely in spite of its "strong development" plans.
06/12/19
MAXM
06/12/19
NO CHANGE
Target $62
MAXM
Buy
Dave & Buster's price target lowered to $62 from $67 at Maxim
Maxim analyst Stephen Anderson lowered his price target on Dave & Buster's to $62 after its "weak" Q1 results, also lowering his Q2 and FY19 estimates by 3c and 17c to 87c and $3.09 respectively following the company's miss on comps. The analyst keeps his Buy rating on Dave & Buster's shares however, stating that he remains "encouraged that virtual reality-related traffic will support FY19 EPS" to levels at or above the high end of lowered guidance. Anderson also lowers his FY20 EPS outlook to $3.62 from $3.91.
06/12/19
LOOP
06/12/19
NO CHANGE
Target $55
LOOP
Buy
Dave & Buster's price target lowered to $55 from $65 at Loop Capital
Loop Capital analyst Lynne Collier lowered her price target on Dave & Buster's to $55 after its Q1 earnings miss and below-consensus comps, with a decrease of 0.3% in blended SSS driven by decelerating food and beverage sales. The analyst also points to the "choppy sales" observed by the management thus far in Q2 and says the volatility in recent performance is disappointing, even though she keeps her Buy rating on the stock and believes that its new valuation already reflects much of the negative news. Collier adds that Dave & Buster's' VR gaming is resonating with consumers and expects the company's menu changes to boost the company's food/beverage comps in the coming months.
TTD Trade Desk
$249.29

-0.71 (-0.28%)

06/05/19
PIVT
06/05/19
NO CHANGE
Target $265
PIVT
Buy
Trade Desk price target raised to $265 from $255 at Pivotal Research
Pivotal Research analyst Michael Levine said he sees continued share gains by Trade Desk (TTD) relative to other DSPs based on data through May, leaving him comfortable with his above consensus forecasts for Q2. However, despite the company's "impressive position" in online, he acknowledges he "may have gotten slightly ahead of [his] skis regarding the ramp in connected TV" in the second half of 2019 and Levine trimmed his estimates for the second half. Greater regulatory scrutiny on Google (GOOG) by the DOJ would be positive for Trade Desk, added Levine, who raised his price target on Trade Desk to $265 from $255 and keeps a Buy rating on the shares.
05/29/19
PIVT
05/29/19
INITIATION
Target $255
PIVT
Buy
Trade Desk initiated with a Buy at Pivotal Research
Pivotal Research analyst Michael Levine started Trade Desk with a Buy rating and $255 price target. The company is "truly unique," growing at among the fastest rates in the industry as it penetrates the opportunity in programmatic advertising, Levine tells investors in a research note.
05/14/19
SBSH
05/14/19
NO CHANGE
Target $205
SBSH
Buy
Trade Desk price target raised to $205 from $195 at Citi
Citi analyst Mark May raised his price target for Trade Desk to $205 from $195 yesterday afternoon saying the company reported revenue and EBITDA results that were again above forecasts. The analyst maintains a Buy rating on the shares. He believes Trade Desk's new initiatives are gaining traction.
06/12/19
NOMU
06/12/19
DOWNGRADE
Target $144
NOMU
Reduce
Trade Desk downgraded to Reduce from Neutral at Nomura Instinet
Nomura Instinet analyst Mark Kelley downgraded Trade Desk to Reduce from Neutral with an unchanged price target of $144. The company's underlying business fundamentals, "while relatively solid, are out of sync with near- to medium-term investor expectations and the story being told," Kelley tells investors in a research note. He believes Trade Desk "isn't outpacing the industry as much as investors think" and that its total addressable market is not $1 trillion. The company's revenue potential is $12B, roughly in line with its $11B market cap, says Kelley.
MDSO Medidata
$94.75

3.97 (4.37%)

05/01/19
DOTC
05/01/19
DOWNGRADE
DOTC
Neutral
Medidata downgraded earlier to Neutral from Buy at Dougherty
06/12/19
JPMS
06/12/19
UPGRADE
Target $92.25
JPMS
Neutral
Medidata upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Sterling Auty upgraded Medidata Solutions (MDSO) to Neutral from Underweight and raised his price target for the shares to $92.25 from $74 after the company agreed to be acquired by Dassault Systemes (DASTY).
06/12/19
WBLR
06/12/19
DOWNGRADE
WBLR
Market Perform
Medidata downgraded to Market Perform from Outperform at William Blair
William Blair analyst Jeffrey Garro downgraded Medidata Solutions (MDSO) to Market Perform from Outperform after the company reached an agreement to be acquired by Dassault Systemes (DASTY).
06/12/19
GUGG
06/12/19
DOWNGRADE
GUGG
Neutral
Medidata downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Glen Santangelo downgraded Medidata (MDSO) to Neutral from Buy after Dassault (DASTY) announced an agreement to acquire the company for $92.25 per share in cash.
LRCX Lam Research
$189.90

-0.18 (-0.09%)

05/10/19
SBSH
05/10/19
DOWNGRADE
SBSH
Neutral
Citi downgrades Entegris and Universal Display to Neutral from Buy
Citi analyst Atif Malik downgraded both Entegris (ENTG) and Universal Display (OLED) to Neutral from Buy. The analyst expects consumable stocks tied to overall wafer or display starts to "slow down" in the second half of 2019. His top picks in Semiconductor Capital Equipment remain Lam Research (LRCX) and Applied Materials (AMAT), which he notes have high exposure to the memory end market. Assuming no recession, Malik believes the group bottomed in Q1 as year-over-year memory supply growth peaked.
04/25/19
SBSH
04/25/19
NO CHANGE
Target $224
SBSH
Buy
Citi ups target on top equipment pick Lam Research to $224
Citi analyst Atif Malik raised his price target for Lam Research to $224 from $215 following the company's "beat and raise" earnings report. The stock typically outperforms the group out of a memory downturn, Malik tells investors in a research note. He says Lam remains his top pick equipment pick with a Buy rating. While Lam continues to expect the DRAM spending correction to last through the end of the year, bit shipments in NAND in the month of February were above seasonal and market conditions are setting up for a recovery of supply/demand balance, contends Malik.
06/12/19
EVER
06/12/19
DOWNGRADE
Target $195
EVER
In Line
Lam Research downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst C.J. Muse downgraded Lam Research to In Line from Outperform and lowered his price target for the shares to $195 from $225. An estimate reset in the second half of 2019, combined with a pushout of a memory recovery to the second half of 2020 from the first half, creates headwinds that will make it difficult for the shares to move higher over the near-term, Muse tells investors in a research note. As a result, the analyst expects to get a better buying opportunity into Lam shares at a later date.
04/25/19
COWN
04/25/19
NO CHANGE
Target $235
COWN
Outperform
Lam Research price target raised to $235 from $223 at Cowen
Cowen analyst Krish Sankar raised his price target for Lam Research to $235 from $223 saying that even with a mostly in line June quarter outlook and limited visibility on a WFE recovery, he views the company's results in a positive light due to the absence of any further deterioration in fundamentals. Modest share losses last year are manageable, he adds. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

AMAG

Amag Pharmaceuticals

$8.97

0.36 (4.18%)

05:49
06/24/19
06/24
05:49
06/24/19
05:49
Recommendations
Amag Pharmaceuticals analyst commentary  »

Piper Jaffray still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPOT

Spotify

$148.17

-1.57 (-1.05%)

05:39
06/24/19
06/24
05:39
06/24/19
05:39
Downgrade
Spotify rating change  »

Spotify downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

UTX

United Technologies

$128.78

-1.25 (-0.96%)

, RTN

Raytheon

$182.79

0.52 (0.29%)

05:38
06/24/19
06/24
05:38
06/24/19
05:38
Upgrade
United Technologies, Raytheon rating change  »

United Technologies…

UTX

United Technologies

$128.78

-1.25 (-0.96%)

RTN

Raytheon

$182.79

0.52 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$33.23

-0.91 (-2.67%)

05:32
06/24/19
06/24
05:32
06/24/19
05:32
Recommendations
Micron analyst commentary  »

Micron price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 09

    Jul

RMTI

Rockwell Medical

$2.99

-0.02 (-0.66%)

05:27
06/24/19
06/24
05:27
06/24/19
05:27
Initiation
Rockwell Medical initiated  »

Rockwell Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SON

Sonoco

$65.40

-0.35 (-0.53%)

05:23
06/24/19
06/24
05:23
06/24/19
05:23
Downgrade
Sonoco rating change  »

Sonoco downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 17

    Oct

NSIT

Insight Enterprises

$56.19

-1.31 (-2.28%)

, PCMI

PCM, Inc.

$24.35

-1.56 (-6.02%)

05:23
06/24/19
06/24
05:23
06/24/19
05:23
Hot Stocks
Insight Enterprises to acquire PCM, Inc. for $35 per share »

Insight Enterprises…

NSIT

Insight Enterprises

$56.19

-1.31 (-2.28%)

PCMI

PCM, Inc.

$24.35

-1.56 (-6.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCC

Boise Cascade

$24.57

-0.83 (-3.27%)

05:16
06/24/19
06/24
05:16
06/24/19
05:16
Upgrade
Boise Cascade rating change  »

Boise Cascade upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$78.42

(0.00%)

05:12
06/24/19
06/24
05:12
06/24/19
05:12
Hot Stocks
Hexcel announces voluntary delisting from Euronext Paris »

Hexcel announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

EVA

Enviva

$29.50

-0.24 (-0.81%)

05:11
06/24/19
06/24
05:11
06/24/19
05:11
Upgrade
Enviva rating change  »

Enviva upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$165.16

-1.8 (-1.08%)

05:10
06/24/19
06/24
05:10
06/24/19
05:10
Hot Stocks
Motorola Solutions awarded tender for supplying POC service to Israel Railways »

Motorola Solutions has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 19

    Dec

CNTY

Century Casinos

$9.83

-0.3 (-2.96%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Century Casinos management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

CNCE

Concert Pharmaceuticals

$10.90

-0.165 (-1.49%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Concert Pharmaceuticals management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

ATH

Athene Holding

$42.58

-0.8 (-1.84%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Athene Holding management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

SSTI

ShotSpotter

$44.50

0.19 (0.43%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
ShotSpotter management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

ATH

Athene Holding

$42.58

-0.8 (-1.84%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Athene Holding management to meet with Sandler ONeill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

HUBG

Hub Group

$40.70

-1.25 (-2.98%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Hub Group management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 13

    Nov

SPOT

Spotify

$148.17

-1.57 (-1.05%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Spotify management to meet with SunTrust »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

INGN

Inogen

$71.29

-1.37 (-1.89%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
William Blair medical tech analyst to hold a luncheon »

Medical Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 26

    Aug

STXB

Spirit of Texas Bancshares

$22.49

0.07 (0.31%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Spirit of Texas Bancshares management to meet with Sandler ONeill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

04:55
06/24/19
06/24
04:55
06/24/19
04:55
General news
Dallas Fed Mfg Survey General Activity Index to be reported at 10:30 »

June Dallas Fed Mfg…

04:55
06/24/19
06/24
04:55
06/24/19
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

INWK

InnerWorkings

$4.17

(0.00%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
InnerWorkings management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

OKTA

Okta

$130.77

-2.63 (-1.97%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Okta management to meet with KeyBanc »

Dinner Meeting with CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

STFC

State Auto Financial

$34.64

-0.18 (-0.52%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
State Auto Financial management to meet with Sandler O'Neill »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.